Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96254e601f92b5fc166cac9c189a8568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3d7e2f8fb5650d7d3616661464b67771 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9eaa0911b707a7cd760547706c911a78 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
filingDate |
2017-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c20a52d04c3178f0ec2cb502c68d60d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ad3d3bb678f3009a4ebbc0562506b92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b1a6ef7287784c867accea7331566f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93310ab157aa57b7885bab2df243b4d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e67e7cca4ee67432a661473160b63cc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44018ebf5e86dddcb8d0d261248f7289 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_253b64449d3ff0925014aa10fd93b6c3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c922e579f2126a84c9511620adf26c58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_713e3aec8dc4f8cc9b2760a31680a087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c7a78fe494e90adcbc2b969c397a8bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89759b4f716b15c001c501cfec2e84bb |
publicationDate |
2020-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10570141-B2 |
titleOfInvention |
Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof |
abstract |
The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11440912-B2 |
priorityDate |
2016-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |